Biomarin Pharmaceutical Inc [NASDAQ: BMRN] jumped around 0.46 points on Thursday, while shares priced at $58.55 at the close of the session, up 0.79%.
Compared to the average trading volume of 1.85M shares, BMRN reached a trading volume of 3982519 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Biomarin Pharmaceutical Inc [BMRN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMRN shares is $96.81 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMRN stock is a recommendation set at 1.52. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Biomarin Pharmaceutical Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 24, 2025. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on November 15, 2024, representing the official price target for Biomarin Pharmaceutical Inc stock.
The Average True Range (ATR) for Biomarin Pharmaceutical Inc is set at 1.73, with the Price to Sales ratio for BMRN stock in the period of the last 12 months amounting to 3.84. The Price to Book ratio for the last quarter was 1.94, with the Price to Cash per share for the same quarter was set at 6.63. Price to Free Cash Flow for BMRN in the course of the last twelve months was 17.99 with Quick ratio for the last quarter at 3.49.
How has BMRN stock performed recently?
Biomarin Pharmaceutical Inc [BMRN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.12. With this latest performance, BMRN shares dropped by -7.47% in over the last four-week period, additionally sinking by -8.89% over the last 6 months – not to mention a drop of -22.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMRN stock in for the last two-week period is set at 43.17, with the RSI for the last a single of trading hit 44.38, and the three-weeks RSI is set at 43.00 for Biomarin Pharmaceutical Inc [BMRN]. The present Moving Average for the last 50 days of trading for this stock 62.43, while it was recorded at 58.06 for the last single week of trading, and 68.54 for the last 200 days.
Biomarin Pharmaceutical Inc [BMRN]: Deeper insight into the fundamentals
Biomarin Pharmaceutical Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.49 and a Current Ratio set at 5.52.
Earnings analysis for Biomarin Pharmaceutical Inc [BMRN]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMRN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biomarin Pharmaceutical Inc go to 33.31%.
Insider trade positions for Biomarin Pharmaceutical Inc [BMRN]
The top three institutional holders of BMRN stocks are: BLACKROCK INC. with ownership of 22.74 million shares, which is approximately 11.9604%. VANGUARD GROUP INC, holding 18.99 million shares of the stock with an approximate value of $$1.56 billion in BMRN stocks shares; and VANGUARD GROUP INC, currently with $$1.55 billion in BMRN stock with ownership which is approximately 9.8836%.
